James Wolberg
Addiction Medicine · New York, NYNPI 1538371331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.
Across 300 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$658
- AbbVie$474
- Axsome Therapeutics, Inc.$363
- Tris Pharma Inc$268
- Johnson & Johnson$240
- plus $2K from 20 others
Across 19 payments — averaging $2084.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$22K
- Jazz Pharmaceuticals Inc.$11K
- Sumitomo Pharma America, Inc.$7K
What the payments were for
- Food & beverage$5,060100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,177 |
| Lundbeck LLC | 39 | $658 |
| AbbVie | 30 | $474 |
| Axsome Therapeutics, Inc. | 20 | $363 |
| Tris Pharma Inc | 17 | $268 |
| Johnson & Johnson | 13 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $239 |
| Otsuka America Pharmaceutical, Inc. | 14 | $236 |
| Corium, LLC | 17 | $235 |
| Teva Pharmaceuticals USA, Inc. | 8 | $166 |
| Sunovion Pharmaceuticals Inc. | 8 | $156 |
| Alkermes, Inc. | 9 | $142 |
| Lilly USA, LLC | 7 | $128 |
| Supernus Pharmaceuticals, Inc. | 4 | $87 |
| Idorsia Pharmaceuticals US Inc | 5 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Ironshore Pharmaceuticals Inc. | 5 | $67 |
| Neurocrine Biosciences, Inc. | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 4 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| Harmony Biosciences LLC | 2 | $39 |
| Alfasigma USA, Inc. | 2 | $26 |
| Neos Therapeutics, LP | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| Indivior Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $12 |
How this compares
$5,072 in reported general payments places this provider in the 85th percentile of 125 addiction medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 16 | $583 |
| Bupropion XlBupropion Hcl | 11 | $194 |
| Clonazepam | 19 | $156 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in New York
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Ramon RaveloNew York$13K
- Stuart GitlowNew York$7K
- Joshua LeeNew York$1K
- Lloyd ZimmermanNew York$1K
- Stephanie SeaslyNew York$829
- James McKnightNew York$694
- Elias DakwarNew York$514
- Alina BabarNew York$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.